<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094416</url>
  </required_header>
  <id_info>
    <org_study_id>13US-T404</org_study_id>
    <nct_id>NCT03094416</nct_id>
  </id_info>
  <brief_title>Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors</brief_title>
  <official_title>An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label therapeutic efficacy study of Tirosint (levothyroxine sodium) capsules
      in thyroidectomized patients taking proton pump inhibitors and levothyroxine, evaluating
      changes in serum levels of TSH upon switch to Tirosint with respect to baseline.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Actual">June 15, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TSH (Thyroid Stimulating Hormone)</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>change in serum levels of TSH upon switch to levothyroxine sodium capsules with respect to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FT4 (free thyroxine)</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>change in serum levels of FT4 with respect to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TT4 (total thyroxine)</measure>
    <time_frame>12 weeks</time_frame>
    <description>change in serum levels of TT4 with respect to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FT3 (free triiodothyronine)</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>change in serum levels of FT3 with respect to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TT3 (total triiodothyronine)</measure>
    <time_frame>6 weeks and 12 weeks</time_frame>
    <description>change in serum levels of TT3 with respect to baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CPK (creatine phosphokinase)</measure>
    <time_frame>12 weeks</time_frame>
    <description>changes in CPK towards baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>SHBG (sex hormone binding globulin)</measure>
    <time_frame>12 weeks</time_frame>
    <description>changes in SHBG towards baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>ferritin</measure>
    <time_frame>12 weeks</time_frame>
    <description>changes in ferritin towards baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>ACE (angiotensin converting enzyme)</measure>
    <time_frame>12 weeks</time_frame>
    <description>changes in ACE towards baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>lipid panel</measure>
    <time_frame>12 weeks</time_frame>
    <description>changes in lipid panel towards baseline</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hypothyroidism;Postablative</condition>
  <arm_group>
    <arm_group_label>levothyroxine sodium capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>levothyroxine sodium capsules 88 to 250 mcg/day (depending on individual needs) for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levothyroxine sodium capsule</intervention_name>
    <description>patients will be switched from their current levothyroxine sodium tablet to levothyroxine sodium capsule</description>
    <arm_group_label>levothyroxine sodium capsules</arm_group_label>
    <other_name>Tirosint</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. written informed consent duly read, signed and dated by the subject;

          2. aged ≥18 and ≤65 years;

          3. history of hypothyroidism due to total thyroidectomy;

          4. on stable LT4 doses for at least 6 weeks at screening (≥88 mcg daily and ≤250 mcg
             daily);

          5. TSH at screening ≥0.3 and ≤4.0 mIU/L;

          6. history of gastroesophageal reflux disease or associated gastrointestinal issues on
             prescription PPIs (i.e. omeprazole ≥20 mg daily, or esomeprazole ≥ 20 mg daily, or
             lansoprazole ≥ 15 mg daily, or pantoprazole ≥ 40 mg daily) for at least 8 weeks before
             screening visit and for whom chronic therapy with PPIs for the next 5 months has been
             prescribed;

          7. for women, adequate and continuative contraceptive measures until the end of the
             study, if not in menopause;

          8. reasonable assumption of understanding the study and willingness to take part to the
             study and to comply with protocol requirements.

        Exclusion Criteria:

          1. suspected or ascertained non-compliance with LT4 or PPI therapy;

          2. subject requiring changes of levothyroxine dose;

          3. use of over-the-counter (OTC) PPIs;

          4. history of malabsorption or history of gastric bypass surgery, short-gut syndrome,
             inflammatory bowel disease and other conditions of the gastrointestinal tract that may
             affect drug absorption (e.g. celiac disease)3;

          5. multiple co-morbidities (e.g. cardiac heart failure, active arrhythmia or history of
             arrhythmia, particularly atrial fibrillation, uncompensated diabetes mellitus,
             uncorrected adrenal insufficiency, seriously compromised hepatic, renal and/or
             respiratory functions);

          6. neoplastic pathology, active or in remission for less than 5 years (excluding the
             basic thyroid pathology);

          7. terminal condition;

          8. parenteral or assisted enteral feeding;

          9. presence of any medical condition or other circumstances which would significantly
             affect the safety of the subject or decrease the chance of obtaining reliable data,
             achieving study objectives or completing the study;

         10. history of alcoholism, drug abuse or psychiatric diseases that could invalidate the
             informed consent or limit the subject compliance with protocol requirements;

         11. pregnant (positive urine pregnancy test at screening or baseline visits) or
             breast-feeding subject or subject planning a pregnancy in the next months;

         12. known hypersensitivity to the ingredients of the preparation involved in the study3;

         13. use of forbidden concomitant medications;

         14. regular consumption of soy and soy derivatives, cotton seed meals, walnuts, and
             dietary fibres;

         15. participation in other clinical studies during the 3 months prior to screening;

         16. presumption of poor reliability/cooperation;

         17. any reason which, in the opinion of the Investigator, would prevent the subject from
             participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth D Burman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>California Head and Neck Specialists</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Metabolic Research Centre</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2975</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYC Health + Hospitals/ Queens</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes &amp; Endocrinology Consultants, PC</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Ear Nose and Throat Clinic</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stonesifer Endocrine Care &amp; Clinical Research Inc., PS</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

